Who Paid My Doc Search
Menu
Organisation paid for research Program year 2021 Source: CMS Open Payments

Compass Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$5,249,131

1,695 payments

Through program year 2021, Compass Research, LLC is reported as receiving $5,249,131 in research payments, across 1,695 payments.

By program year

3 rows
Year Kind Amount Payments
2021 Research $62 1
2020 Research $2,540,529 902
2019 Research $2,708,540 792

Breakdown

Who paid Research payments · program years 2019–2021
  1. Eisai Inc. $4,431,507 1,650 payments
  2. Nevro Corp. $408,882 23 payments
  3. Biogen, Inc. $208,787 3 payments
  4. Acorda Therapeutics, Inc $124,171 5 payments
  5. Avanir Pharmaceuticals, Inc. $75,722 13 payments
  6. Merck Sharp & Dohme Corporation $62 1 payment
Studies the money was for Research payments · program years 2019–2021
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $2,721,102 1,021 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,006,713 493 payments
  3. A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $408,854 1 payment
  4. Chronic Peripheral Polyneuropathy Randomized Trial $400,804 21 payments
  5. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $207,977 2 payments
  6. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease $163,015 62 payments
  7. Cvt-301-012 $99,823 2 payments
  8. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $63,078 29 payments
  9. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies $51,411 32 payments
  10. 15-Avp-786-302 $48,715 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record